Anti-Human IL5 Recombinant Antibody (TAB-031)

Recombinant monoclonal antibody to Human IL5. It is a humanized monoclonal antibody that recognizes interleukin-5 (IL-5) and is used to treat certain kinds of asthma and white blood cell diseases. Recent studies have concluded that mepolizumab may improve exacerbations in patients with severe eosinophilic asthma, an adult-onset asthma that represents less than 5% of all asthma. IL-5 is a chemical messenger in the immune system that stimulates the growth of eosinophils. In eosinophilic asthma, eosinophils are present in the lungs. When mepolizumab was given to people with eosinophilic asthma, it eliminated eosinophils from the bloodstream and reduced eosinophils in the lungs and bone marrow. It is designed to support reliable, reproducible results in modern laboratories. It helps streamline your workflow, reduce troubleshooting, and deliver consistent performance across batches. Prominent attributes include productname and abbr.

Manufactured under rigorous quality controls, each lot is checked for key specifications to ensure lot‑to‑lot consistency. The format is optimized for ease of use and integration into existing protocols, with documentation available upon request.

Key Features / Benefits

• productname: Anti-Human IL5 Recombinant Antibody (TAB-031)
• abbr: Anti-IL5 Antibody (TAB-031)
• Target: IL5
• Host Animal: Mouse
• Specificity: Tested positive against native human antigen
• Immunogen: Recombinant human IL5.

Relevant Applications

• IF
• IP
• Neut
• FuncS
• ELISA
• FC
• ICC
• The IL5 antibody has been reported in applications of Activ